New FDA-Approved Alzheimer’s Blood Test Coming to Mayo Clinic
- The FDA approved the Lumipulse blood test to help diagnose Alzheimer's disease in people aged 55 and older in clinical settings.
- The approval follows recent advances in Alzheimer's research focused on improving diagnosis speed and accuracy to enable earlier treatment.
- Fujirebio will distribute the test to 37 US Alzheimer's clinics, including Mayo Clinic, which plans to run up to 5,000 tests monthly.
- A Mayo Clinic study on 500+ patients showed the test has 95% sensitivity and 82% specificity, matching invasive cerebrospinal fluid tests in accuracy.
- This test may accelerate diagnosis and treatment access, improving outcomes as disease-modifying therapies become available and prompting similar UK adoption efforts.
12 Articles
12 Articles
New blood test for Alzheimer's with 95% accuracy may soon be on the NHS
A new blood test for Alzheimer’s disease can accurately detect people with early symptoms, according to research which experts hope to build on and bring us closer to a cure.Scientists from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia, by examining two proteins in blood plasma. These proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque build-up, whic…


Alzheimer’s blood test ‘can accurately pick up early symptoms’
Researchers found the blood test was 95% accurate in picking up people with the disease, with very few cases missed.
New FDA-approved Alzheimer’s blood test coming to Mayo Clinic
The U.S. Food and Drug Administration has approved the marketing of a new tool to that can test a person’s blood to diagnose Alzheimer's disease. The blood test is a groundbreaking development to confirm the disease in patients who are already experiencing cognitive decline.
Coverage Details
Bias Distribution
- 75% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage